Diabetology International

, Volume 5, Issue 2, pp 117–121

Evaluation of thrice-daily injections of insulin Lispro Mix 50/50 versus basal-bolus therapy in perioperative patients with type 2 diabetes

  • Kyu Yong Cho
  • Osamu Nakagaki
  • Hideaki Miyoshi
  • Kazumasa Akikawa
  • Tatsuya Astumi
Original Article
  • 160 Downloads

Abstract

Purpose

The purpose of this study was to compare two perioperative insulin therapies [thrice-daily injections of insulin Lispro Mix 50/50 (3X-Mix50) versus basal-bolus injections (BBT)] in type 2 diabetic patients who were judged by attending endocrinologists to require intensive insulin treatment before surgery.

Materials and methods

A retrospective analysis was performed on data collected from 47 surgical patients hospitalized at Obihiro-Kosei General Hospital and treated with BBT (n = 27) or 3X-Mix50 (n = 20) for 1 year.

Results

Patient baseline characteristics (age, duration of diabetes, BMI, FPG and HbA1c) were similar between therapeutic groups. Both therapies achieved target glycemic control for surgery in 9 days on average. There was no significant difference in average pre-meal or bedtime blood glucose levels. The total daily insulin dose before surgery was similar (28.3 U in BBT vs. 24.8 U in 3X-Mix50, p = 0.1146). No episodes of severe hypoglycemia occurred, and the number of episodes of mild hypoglycemia during the perioperative period was similar. No surgical complications such as infection occurred, and one orthopedic surgery-related issue occurred in each therapeutic group.

Conclusion

We showed 3X-Mix50 and BBT were comparable in terms of glycemic control, total insulin dose, and incidence of hypoglycemia and perioperative complications. While comparable to classical BBT therapy, the 3X-Mix50 provides a convenient alternative method for maintaining glycemic control in patients with type 2 diabetes during the perioperative period.

Keywords

Type 2 diabetes Insulin Lispro Mix 50/50 Basal-bolus therapy Perioperative period Surgical complications 

References

  1. 1.
    Doenst T, Wijeysundera D, Karkouti K, Zechner C, Maganti M, Rao V, et al. Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2005;130:1144.PubMedCrossRefGoogle Scholar
  2. 2.
    Estrada CA, Young JA, Nifong LW, Chitwood WR Jr. Outcomes and perioperative hyperglycemia in patients with or without diabetes mellitus undergoing coronary artery bypass grafting. Ann Thorac Surg. 2003;75:1392–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care. 1992;15:256–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Turina M, Fry DE, Polk HC Jr. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Crit Care Med. 2005;33:1624–33.PubMedCrossRefGoogle Scholar
  5. 5.
    Bower WF, Lee PY, Kong AP, Jiang JY, Underwood MJ, Chan JC, et al. Peri-operative hyperglycemia: a consideration for general surgery? Am J Surg. 2010;199:240–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Okabayashi T, Ichikawa K, Namikawa T, Sugimoto T, Kobayashi M, Hanazaki K. Effect of perioperative intensive insulin therapy for liver dysfunction after hepatic resection. World J Surg. 2011;35:2773–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008;31:20–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Polonsky WH, Anderson BJ, Lohrer PA, Welch G, Jacobson AM, Aponte JE, et al. Assessment of diabetes-related distress. Diabetes Care. 1995;18:754–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes. 1997;46:440–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Res Clin Pract. 2006;73:35–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–47.PubMedCrossRefGoogle Scholar
  12. 12.
    Schernthaner G, Kopp HP, Ristic S, Muzyka B, Peter L, Mitteregger G. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70. Horm Metab Res. 2004;36:188–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med. 1998;15:297–303.PubMedCrossRefGoogle Scholar
  14. 14.
    Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia. 2004;47:31–9.PubMedCrossRefGoogle Scholar

Copyright information

© The Japan Diabetes Society 2013

Authors and Affiliations

  • Kyu Yong Cho
    • 1
  • Osamu Nakagaki
    • 1
  • Hideaki Miyoshi
    • 1
  • Kazumasa Akikawa
    • 2
  • Tatsuya Astumi
    • 1
  1. 1.Hokkaido University School of MedicineSapporoJapan
  2. 2.Obihiro-Kosei General HospitalObihiroJapan

Personalised recommendations